Clinical TrialsBenitec Biopharma has made steady advances with the Phase 1b/2a trial of its lead clinical candidate, BB-301, with the sixth subject being safely treated with the low dose.
Financial PerformanceBenitec Biopharma recorded a F3Q25 net loss of only $0.24 per share vs. the forecast of a net loss of $0.36 per share.
Regulatory PathwayAnalysts see a straightforward path to an approvable profile for BB-301 in oculopharyngeal muscular dystrophy, where current treatment options are limited and invasive.